Free Trial

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $17.80 Consensus PT from Brokerages

Artiva Biotherapeutics logo with Medical background

Key Points

  • Artiva Biotherapeutics, Inc. has received a consensus rating of "Buy" from six analysts, with an average one-year price target of $17.80.
  • Recent changes in institutional investor positions include a 250.7% increase in holdings by JPMorgan Chase & Co., highlighting growing interest in the company.
  • Artiva reported earnings of ($0.87) per share, missing estimates, with analysts predicting a full-year EPS of -4.95.
  • Looking to export and analyze Artiva Biotherapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Buy" from the four ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $17.00.

ARTV has been the subject of several research analyst reports. HC Wainwright upgraded shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 target price for the company in a research report on Wednesday, June 11th. Needham & Company LLC dropped their target price on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, May 15th.

Get Our Latest Stock Analysis on ARTV

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter worth $53,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at $67,000. Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at $58,000. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $48,000.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV traded down $0.07 on Tuesday, reaching $2.63. 9,736 shares of the company's stock were exchanged, compared to its average volume of 228,941. The stock has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $2.91. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). Equities analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Further Reading

Should You Invest $1,000 in Artiva Biotherapeutics Right Now?

Before you consider Artiva Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.

While Artiva Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines